[Comment] Reassessing sotrovimab's role in COVID-19: insights and implications

The development of anti-spike monoclonal antibodies by pharmaceutical manufacturers during the COVID-19 pandemic was an unprecedented effort that helped save thousands of lives. In this issue of The Lancet Infectious Diseases, the RECOVERY Collaborative Group provides another milestone of evidence in the management of COVID-19, namely the efficacy of sotrovimab.1 Among the anti-spike monoclonal antibodies authorized so far, sotrovimab is probably the most resilient in treating patients who have been admitted to hospital.